Solistaa Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.50 Cr
as on 04-01-2025
- Paid Up Capital ₹ 4.15 Cr
as on 04-01-2025
- Company Age 7 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 31.56 Cr
as on 04-01-2025
- Satisfied Charges ₹ 33.75 Cr
as on 04-01-2025
- Revenue 73.01%
(FY 2022)
- Profit 63.75%
(FY 2022)
- Ebitda 16.39%
(FY 2022)
- Net Worth 9.78%
(FY 2022)
- Total Assets 37.38%
(FY 2022)
About Solistaa Pharmaceuticals
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.50 Cr and a paid-up capital of Rs 4.15 Cr.
The company currently has active open charges totaling ₹31.56 Cr. The company has closed loans amounting to ₹33.75 Cr, as per Ministry of Corporate Affairs (MCA) records.
Paramasivan Sivarajakumar, Sundararajalu, and Kandoth Vinupal serve as directors at the Company.
- CIN/LLPIN
U24304PY2017PTC008222
- Company No.
008222
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Nov 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pondicherry
Industry
Company Details
- Location
Pondicherry, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Solistaa Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kandoth Vinupal  | Director | 27-Nov-2017 | Current |
| Paramasivan Sivarajakumar | Director | 27-Nov-2017 | Current |
| Sundararajalu | Director | 30-Jan-2018 | Current |
Financial Performance of Solistaa Pharmaceuticals.
Solistaa Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 73.01% increase. The company also saw a substantial improvement in profitability, with a 63.75% increase in profit. The company's net worth moved up by a moderate rise of 9.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Solistaa Pharmaceuticals?
In 2022, Solistaa Pharmaceuticals had a promoter holding of 96.97% and a public holding of 3.03%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 13 Nov 2024 | ₹2.60 Cr | Open |
State Bank Of India Creation Date: 15 Apr 2024 | ₹18.75 Cr | Open |
Sidbi Creation Date: 26 Mar 2024 | ₹1.65 Cr | Open |
How Many Employees Work at Solistaa Pharmaceuticals?
Solistaa Pharmaceuticals has a workforce of 119 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Solistaa Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Solistaa Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
